Your browser doesn't support javascript.
loading
Attenuation of Type IV pili activity by natural products.
Yalkut, Kerem; Ben Ali Hassine, Soumaya; Basaran, Esra; Kula, Ceyda; Ozcan, Aslihan; Avci, Fatma Gizem; Keskin, Ozlem; Sariyar Akbulut, Berna; Ozbek, Pemra.
Afiliação
  • Yalkut K; Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
  • Ben Ali Hassine S; Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
  • Basaran E; Department of Bioengineering, Faculty of Engineering and Natural Sciences, Uskudar University, Istanbul, Turkey.
  • Kula C; Graduate School of Sciences and Engineering, Koc University, Istanbul, Turkey.
  • Ozcan A; Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
  • Avci FG; Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
  • Keskin O; Department of Bioengineering, Faculty of Engineering and Natural Sciences, Uskudar University, Istanbul, Turkey.
  • Sariyar Akbulut B; Graduate School of Sciences and Engineering, Koc University, Istanbul, Turkey.
  • Ozbek P; Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
J Biomol Struct Dyn ; : 1-11, 2024 Feb 02.
Article em En | MEDLINE | ID: mdl-38305801
ABSTRACT
The virulence factor Type IV pili (T4P) are surface appendages used by the opportunistic pathogen Pseudomonas aeruginosa for twitching motility and adhesion in the environment and during infection. Additionally, the use of these appendages by P. aeruginosa for biofilm formation increases its virulence and drug resistance. Therefore, attenuation of the activity of T4P would be desirable to control P. aeruginosa infections. Here, a computational approach has been pursued to screen natural products that can be used for this purpose. PilB, the elongation ATPase of the T4P machinery in P. aeruginosa, has been selected as the target subunit and virtual screening of FDA-approved drugs has been conducted. Screening identified two natural compounds, ergoloid and irinotecan, as potential candidates for inhibiting this T4P-associated ATPase in P. aeruginosa. These candidate compounds underwent further rigorous evaluation through molecular dynamics (MD) simulations and then through in vitro twitching motility and biofilm inhibition assays. Notably, ergoloid emerged as a particularly promising candidate for weakening the T4P activity by inhibiting the elongation ATPases associated with T4P. This repurposing study paves the way for the timely discovery of antivirulence drugs as an alternative to classical antibiotic treatments to help combat infections caused by P. aeruginosa and related pathogens.Communicated by Ramaswamy H. Sarma.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article